In 4Q15, Sanofi earned $7 million from Praluent. The drug received approval in the US in July 2015 and earned $11 million in fiscal 2015. Regeneron Pharmaceuticals (REGN) co-markets the drug with ...

During the first quarter of 2016, Praluent sales came to $13 million. The product sales were recorded by Sanofi (SNY). Regeneron (REGN) records its share of profits or losses from the sale of the ...

MIAMI, United States - The anti-cholesterol drug Praluent (alirocumab), made by France's Sanofi Pharmaceuticals, is linked to a 15 percent lower risk of major cardiovascular events like heart attack ...

Praluent is supplied in 2 dosage strengths, 75mg/mL and 150mg/mL, in a single-dose prefilled pen. In children aged 8 to 11 years, Praluent should be given by a caregiver following proper training.

I then started Praluent injections twice a month to control my cholesterol, which has been incredibly effective — maybe even too effective — and is the purpose of my writing to you.

If the diagnosis of FH is certain, I advise you to continue taking Praluent, as it is likely to have a very large improvement in your chances of getting a heart attack.

Sanofi and Regeneron will be able to continue to sell their cholesterol-lowering drug Praluent in the US while its legal dispute with rival Amgen wends its way through the courts. That was the verdict ...

The Food and Drug Administration (FDA) has approved Praluent (alirocumab) as an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults with homozygous familial ...